MannKind Corp INFLO-1 Data Readout Transcript
Good afternoon, and welcome to the MannKind Corporation conference call to discuss the Phase 1b results for nintedanib DPI. As a reminder, this call is being recorded on July 29, 2026, and will be available for replay on the MannKind Corporation website shortly after this call for approximately 90 days.
This call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from these expectations. For further information on the company's risk factors, please see the Form 10-Q for the period ended March 31, 2026, this morning's press release, and the slides prepared for this presentation.
Joining us this morning are Mike Castagna, Chief Executive Officer; and Dr. Wassim Fares, Senior Vice President and Therapeutic Area Head, Respiratory. I'd now like to turn the conference over to Mr. Castagna.
Thanks, operator, good afternoon, everyone. Thank you for joining us for this focus
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
